Today's Medical & Research News
Chromatography
Investigators at Amgen, Inc. have published new data on chromatography
November 7th, 2009
"Two major aggregation pathways observed in an IgG2 molecule are described. Different aggregate species generated by long-term incubation of the antibody at 37 degrees C were collected by a semi-preparative size exclusion chromatography method," scientists in the United States report. "These purified species were analyzed extensively by denaturing size-exclusion chromatography methods. The major aggregation pathway at low pH (4.0) resulted in the formation of both dimers and high molecular weight (HMW) aggregates. It was found that these dimers and HMW aggregates contain antibody molecules that have a peptide bond cleavage between an aspartic acid and proline residue in the CH2 domain. Evidence that unfolding of the CH2 domain may be driving the aggregation at low pH is presented. At higher pH (pH - 6.0), formation of a dimer having approximately 75% covalent character was the major aggregation pathway while formation of higher molecular weight aggregates were largely suppressed. The covalent dimer consisted of both disulfide linked antibody molecules and another species (similar to 26%) that was formed due to nondisulfide covalent bonds between two heavy chains. At pH - 5.0, both dimer and higher molecular weight aggregates were formed and the aggregation pathway was a combination of the major pathways observed at pH - 4.0 and 6.0. The dimer species formed at pH - 5.0 had a larger contribution from covalent species-both disulfide and nondisulfide linked, while the HNM aggregate contained a higher percentage of molecules that had the peptide bond cleavage in the CH2 domain. The dimer formed at pH - 6.0 was found to have identical secondary and tertiary structure as the intact antibody molecule," wrote N. Vanburen and colleagues, Amgen, Inc. The researchers concluded: "However, the dimer and higher molecular weight aggregate formed at pH - 4.0 have altered secondary and tertiary structure." Vanburen and colleagues published their study in the Journal of Pharmaceutical Sciences (Elucidation of Two Major Aggregation Pathways in an IgG2 Antibody. Journal of Pharmaceutical Sciences, 2009;98(9):3013-3030). For additional information, contact J. Jacob, Amgen Inc., Analyt & Formulat Science, 1201 Amgen Ct, Seattle, WA 98119, USA. The publisher's contact information for the Journal of Pharmaceutical Sciences is: John Wiley & Sons Inc., 111 River St., Hoboken, NJ 07030, USA. Keywords: United States, Seattle, Amgen Inc., Biotechnology Business, Biotechnology Company, Chromatography, Pharmaceutical Business, Pharmaceutical Company, Pharmaceutical Sciences, Pharmaceuticals, Amgen, Inc. This article was prepared by NewsRx editors from staff and other reports. Copyright 2009, NewsRx.com.
|
